ClinicalTrials.gg
CompletedNCT00810030FER-IBD-CORUpdated Dec 21, 2012

FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR

A Phase 3 interventional study of Ferric carboxymaltose and Iron Sucrose in Inflammatory Bowel Disease, Anemia and Iron Deficiency, sponsored by Vifor Pharma. Completed at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-12-21.

Sponsored by Vifor Pharma (part of CSL Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
484
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Inflammatory Bowel Diseases with a site in Austria — 7 open to participants now, 10 under way, 5 of them phase 3. Inflammatory Bowel Diseases · Austria.

Enrollment
11th of 29
484 · median 297
Started
2008
with 1 other
Phase 3
17 of 35
3 open now
Registered
3rd of 35
by date

Among the 35 studies in Inflammatory Bowel Diseases with a site in Austria, this one is the 11th largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2008, is one of 17 in phase 3, and was the 3rd registered.

Inflammatory Bowel Diseases

1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

7 of the 35 studies in Inflammatory Bowel Diseases with a site in Austria are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 116 (42%) stop at 75 or younger; 76 take children under 18; 61 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Inflammatory Bowel Diseases with a site in Austria, or all of them as a file.
02

Study summary

The purpose of this study is to determine how safe, tolerable and effective the new standardised dosage regimen of FERINJECT® infusions is, compared with a well established intravenous iron treatment.

Read the detailed description

Anaemia in inflammatory bowel disease is mainly attributed to iron deficiency. The main cause of anaemia in IBD patients is chronic blood loss. This means that the iron storage depot in IBD patients is always low and should be replenished. Oral iron therapy is the first choice in many cases because of its safety and economy. However, in patients with gastrointestinal bleeding, the effectiveness of oral therapy is reduced. Additionally, oral iron preparations are frequently associated with gastrointestinal adverse reactions.

According to European Guidelines, the preferred route of iron supplementation in IBD is intravenous. Absolute indications for intravenous iron include severe anaemia (Hb \<10 g/dL). The current study is a part of a programme investigating the efficacy and safety of FERINJECT®, a new formulation of parenteral iron (5% weight per volume iron containing ferric carboxymaltose in a solution of water for injection).

The efficacy and safety of FERINJECT® were investigated in a prospective, randomised, controlled study conducted in IBD patients. According to the results of this study, FERINJECT® provides a faster Hb response, a higher increase in iron storage and a better patient tolerance compared to oral preparations. In this study, the iron amount required was calculated according to the Ganzoni formula, where 500 mg is the amount of storage iron. To simplify the treatment and to make the treatment more effective, a new standardised dosage regimen was created. The current study is designed to assess whether this new standardised dosage regimen of i.v. FERINJECT® is as safe and effective as the currently used individually calculated dosage regimen.

The efficacy and safety of the new standardised dosage regimen of FERINJECT® will be compared with an already established, well-known treatment of IDA with iron sucrose (VENOFER®). Iron sucrose (VENOFER®) is assessed to be effective and well-tolerated in the treatment of IDA in IBD patients.

The study is a phase IIIb, multi-centre, randomised, prospective, open-label, controlled study performed at 83 study centres in 14 European countries.

The primary objective of the study is to evaluate the non-inferiority in efficacy of a standardised dosage regimen of FERINJECT® compared to individually calculated dosage regimens of VENOFER® in the correction of IDA in patients with IBD in remission. The secondary objective is to evaluate the safety and tolerability of a standardised correction dose regimen of FERINJECT®.

Approximately 420 patients will be randomised (1:1 randomisation) to receive treatment with either a standardised correction dosage regimen of FERINJECT® or individually calculated dosage regimens of VENOFER®.

Screening will start between 14 and 7 days before the first infusion is administered. Baseline assessments will be performed on Day 1 before the first infusion.

During the screening period, patients will be selected based on eligibility criteria. Patients who meet all of the inclusion criteria and none of the exclusion criteria will undergo baseline assessments at Baseline (Day 1) prior to the first dose of study medication.

Patients randomised to the FERINJECT® group will receive between 500 mg and 2000 mg of FERINJECT®, according to their Hb and body weight, in up to 3 infusions. The maximum infused weekly dose of will be 1000 mg. For patients in the VENOFER® group, the individual iron deficit will be calculated per individual using the modified formula of Ganzoni. Patients will receive one infusion of 200 mg of VENOFER® twice a week, up to 11 infusions, depending on their calculated iron deficit. Due to the relatively large doses of iron being administered, patients will be monitored carefully throughout the study for symptoms of iron overload.

All patients will return for assessment of efficacy and safety at Weeks 4, 8, and 12. The maximum study duration for a patient is 14 weeks. Patients who are not anaemic at Week 12 will be invited to continue to participate in a maintenance study (FER-IBD-07-MAIN), i.e. a study of FERINJECT® versus placebo to determine if the treatment of iron deficiency can prevent the recurrence of anaemia.

03

Conditions studied

  • Inflammatory Bowel Disease
  • Anemia
  • Iron Deficiency
  • Iron-Deficiency Anemia
  • Crohn's Disease
  • Ulcerative Colitis

Keywords

  • ferric carboxymaltose
  • iron sucrose
  • Iron-Deficiency Anemia
  • Crohn's Disease
  • Ulcerative Colitis
  • Ferritin
  • Transferrin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed .
  • Patients ≥18 years of age suffering from mild IBD (CD/UC) or in remission (mild IBD defined as CDAI score \<220, or CAI score ≤7, remission defined as CDAI score \<150, or CAI score ≤4).
  • 7-12 g/dL (female) or 7-13 g/dL (male).
  • Ferritin \<100 μg/L.
  • Normal levels of vitamin B12 and folic acid.
  • Females of must have a negative urine pregnancy test at screening and be practising an acceptable method of during the study and for up to 1 month after the last dose of study medication.

Exclusion criteria

Exclusion Criteria

  • Chronic alcohol abuse (alcohol consumption >20 g/day).
  • Presence of portal hypertension with oesophageal varices.
  • History of erythropoietin, intravenous or oral iron therapy, or blood transfusion in 4 weeks prior to screening.
  • Known to FERINJECT®.
  • History of acquired iron overload.
  • Myelodysplastic syndrome.
  • Pregnancy or lactation.
  • Known active infection, overt bleeding, active .
  • Known chronic renal failure. Vifor Pharma - Vifor (International) Inc Clinical Study Protocol inc. Amendments 1 and 2 Protocol Number: 93842, FER-IBD-07-COR CONFIDENTIAL Final 20 of 48 10 December 2008
  • Surgery with relevant blood loss (defined as drop \<2 g/dL) in the last 3 months prior to screening or planned surgery within the following 3 months.
  • Chronic liver disease or increase of liver enzymes ( ([ALT], aspartate aminotransferase [AST]) >3 times the .
  • Known (HIV)/acquired immunodeficiency syndrome (AIDS), virus (HBV) or virus (HCV) infection.
  • Inability to fully comprehend and/or perform study procedures in the investigator's opinion.
  • Participation in any other interventional study within 1 month prior to screening.
  • Body weight \<35 kg.
  • Significant cardiovascular disease, including myocardial infarction within 12 months prior to study inclusion, congestive heart failure (New York Heart Association) grade III or IV, or poorly controlled hypertension according to the judgment of the investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
484 participants (actual)

Study arms

  • Experimental
    FERINJECT® (Ferric carboxymaltose)

    Drug: Ferric carboxymaltose

  • Active comparator
    VENOFER® (Iron Sucrose)

    Drug: Iron Sucrose

Interventions

  • Dosage form: 5% w/v iron containing 50 mg iron per mL, as sterile solution of FERINJECT® in water for injection. In case of drip infusion FERINJECT® (10 to 20 ml) must be diluted only in sterile 0.9% sodium chloride (max 250 ml) FERINJECT® will be administered via i.v. drip infusion. Minimum administration time 15 minutes Dosage: 500 mg, 1000 mg, 1500 mg, according to patients' Hb and body weight

    Also known as: FERINJECT®

  • VENOFER® will be administered via i.v. drip infusion, diluted only in sterile 0.9% sodium chloride solution as follows: • 10 mL Venofer® (200 mg iron) in maximum 200 mL sterile 0.9% sodium chloride solution in at least 30 minutes. The first 25 mL of solution should be infused as a test dose over a period of 15 minutes. If no adverse reactions occur, use infusion rate no more than 50 mL in 15 minutes. The individual iron deficit will be calculated using the modified formula of Ganzoni. If the patient's body mass index is \>25, a normalised weight will be used for the calculation of iron deficit. Normalised weight = 25 x height \[m\] x height \[m\]. The calculated cumulative VENOFER® dose is to be rounded up or down to the nearest 200 mg. Patients will receive one 200 mg VENOFER® infusion, twice a week, up to 11 times (max dosage 2200 mg), depending on their calculated iron deficit.

    Also known as: VENOFER®

06

What researchers measure

Primary outcomes

  1. Number of responders with respect to the baseline Hb value.

    Number of responders (Hb increase ≥2 g/dL) with respect to the baseline Hb value.

    Time frame: 12 weeks post baseline

Secondary outcomes

  1. Number of patients whose Hb increased ≥2 g/dL or who reached normal Hb levels at Week 12.

    The number of patients who achieved increase of Hb ≥2 g/dL or the normal range of Hb value of Hb ≥12 (female) or ≥13 (male) g/dL) at Week 12.

    Time frame: 12 weeks post baseline

  2. Change in disease activity (CDAI, CAI, C-reactive protein [CRP]).

    Change in disease activity (Crohn's Disease Activity Index \[CDAI\], Colitis Activity Index \[CAI\], C-reactive protein \[CRP\]) at Week 12.

    Time frame: 12 weeks post baseline

  3. The number of patients at Week 12: TfS: 20 to 50%.

    The number of patients at Week 12: TfS: 20 to 50%.

    Time frame: 12 weeks post baseline

  4. The number of non-anaemic patients at Week 12

    The number of non-anaemic patients at Week 12: Hb ≥12 (female) or ≥13 (male) g/dL.

    Time frame: Week 12 post baseline

  5. The number of patients with ferritin >100 µg/L at Week 12.

    The number of patients with ferritin \>100 µg/L at Week 12.

    Time frame: 12 weeks post baseline

  6. Maximum increase in Hb, serum ferritin and TfS.

    Maximum increase in Hb, serum ferritin and TfS.

    Time frame: 12 weeks post baseline

  7. The number of patients at achieving Hb ≥12 (female) or ≥13 (male) g/dL and ferritin >100 µg/L at Week 12.

    The number of patients at Week 12: Hb ≥12 (female) or ≥13 (male) g/dL and ferritin \>100 µg/L.

    Time frame: 12 weeks post baseline

  8. The number of patients withdrawal from study due to protocol procedure.

    The number of patients withdrawal from study due to protocol procedure.

    Time frame: 12 weeks post baseline

  9. The number of responders (Hb increase ≥2 g/dL) with respect to treatment of underlying disease.

    The number of responders (Hb increase ≥2 g/dL) with respect to treatment of underlying disease.

    Time frame: 12 weeks post baseline

  10. The number of patients with Hb baseline value ≤10 g/dL who achieved Hb increase ≥2 g/dL and the number of patients with Hb baseline value >10 g/dL who achieved Hb increase ≥2 g/dL.

    The number of patients with Hb baseline value ≤10 g/dL who achieved Hb increase ≥2 g/dL and the number of patients with Hb baseline value \>10 g/dL who achieved Hb increase ≥2 g/dL.

    Time frame: 12 weeks post baseline

  11. Change in health-related quality of life (QoL) from baseline to Week 12 using the Short Form (SF)-36, version 2 and IBDQ.

    Change in health-related quality of life (QoL) from baseline to Week 12 using the Short Form (SF)-36, version 2 and IBDQ.

    Time frame: 12 weeks post baseline

  12. The number of patients out of work due to anaemia or IBD.

    The number of patients out of work due to anaemia or IBD.

    Time frame: 12 weeks post baseline

  13. Days out of hospital.

    Days out of hospital.

    Time frame: 12 weeks post baseline

  14. Hospitalisation rate

    Hospitalisation rate (hospitalisation due to anaemia and/or IBD).

    Time frame: 12 weeks post baseline

  15. Adverse events: type, nature, incidence and outcome.

    Adverse events: type, nature, incidence and outcome.

    Time frame: 12 weeks post baseline

  16. Vital signs (blood pressure, pulse rate and bw).

    Vital signs (blood pressure, pulse rate and bw).

    Time frame: 12 weeks post baseline

  17. Electrocardiogram.

    Electrocardiogram.

    Time frame: 12 weeks post baseline

  18. Change in laboratory parameters (haematology, clinical chemistry, iron status, urinalysis).

    Change in laboratory parameters (haematology, clinical chemistry, iron status, urinalysis).

    Time frame: 12 weeks post baseline

  19. Physical examination.

    Physical examination.

    Time frame: 12 weeks post baseline

  20. The number of responders (Hb increase ≥2 g/dL) with respect to the baseline Hb value.

    The number of responders (Hb increase ≥2 g/dL) with respect to the baseline Hb value.

    Time frame: 12 weeks post baseline

07

Study locations

1 site
  • AKH Vienna, University clinic of Int Medizin III
    Vienna, 1090, Austria
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Dec 2009 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2008
First posted
Dec 17, 2008
Start
Oct 2008
Primary completionActual
Dec 2009
CompletionActual
Apr 2010
Last update
Dec 21, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00810030
Lead sponsor
Vifor Pharma
Collaborators
Parexel, ClinStar, LLC
Responsible party
Sponsor
First posted
Dec 17, 2008
Start date
Oct 2008
Primary completion
Dec 2009
Completion
Apr 2010
Last update
Dec 21, 2012

Study contacts

Christoph Gasche, Professor
principal investigator · Medical University of Vienna

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion